Aspirin increases nitric oxide formation in chronic stable coronary disease

Scott Hetzel, David DeMets, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany, Henning Schröder, Charles H. Hennekens

Research output: Contribution to journalArticle

Abstract

Introduction: There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation. Materials and Methods: In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.5, 325, 650, or 1300 aspirin for 12 weeks. Primary prespecified outcome measures were changes in heme oxygenase (HO-1), a downstream target of NO formation, and asymmetrical dimethyl arginine (ADMA), a competitive inhibitor of NO synthase. Results: There were no significant differences for HO-1 or ADMA between any of the clinically relevant doses of aspirin tested, so all were combined. For HO-1, there was a significant increase (10.29 ± 2.44, P <.001) from baseline (15.37 ± 1.85) to week 12 (25.66 ± 1.57). The mean ratio (MR) of week 12 to baseline for HO-1 was significantly higher than 1.0 (1.67, confidence interval [CI] from 1.60 to 1.74, P <.001). For ADMA, there was a significant decrease (-0.24 ± 0.11, P <.001) from baseline (0.78 ± 0.08) to week 12 (0.54 ± 0.07). The MR of week 12 to baseline for ADMA was significantly lower than 1.0 (0.69, CI from 0.66 to 0.73, P <.001). Conclusions: In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA. These are the first randomized data on secondary prevention patients. These data support the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume18
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Aspirin
Coronary Disease
Nitric Oxide
Arginine
Secondary Prevention
Confidence Intervals
Heme Oxygenase-1
Cardiology
Vascular Diseases
Nitric Oxide Synthase
Atherosclerosis
Outcome Assessment (Health Care)
Research

Keywords

  • Aspirin
  • Atherosclerosis (4 limit = 5)
  • Nitric oxide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Hetzel, S., DeMets, D., Schneider, R., Borzak, S., Schneider, W., Serebruany, V., ... Hennekens, C. H. (2013). Aspirin increases nitric oxide formation in chronic stable coronary disease. Journal of Cardiovascular Pharmacology and Therapeutics, 18(3), 217-221. https://doi.org/10.1177/1074248413482753

Aspirin increases nitric oxide formation in chronic stable coronary disease. / Hetzel, Scott; DeMets, David; Schneider, Ricky; Borzak, Steven; Schneider, Wendy; Serebruany, Victor; Schröder, Henning; Hennekens, Charles H.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 18, No. 3, 05.2013, p. 217-221.

Research output: Contribution to journalArticle

Hetzel, S, DeMets, D, Schneider, R, Borzak, S, Schneider, W, Serebruany, V, Schröder, H & Hennekens, CH 2013, 'Aspirin increases nitric oxide formation in chronic stable coronary disease', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 3, pp. 217-221. https://doi.org/10.1177/1074248413482753
Hetzel, Scott ; DeMets, David ; Schneider, Ricky ; Borzak, Steven ; Schneider, Wendy ; Serebruany, Victor ; Schröder, Henning ; Hennekens, Charles H. / Aspirin increases nitric oxide formation in chronic stable coronary disease. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2013 ; Vol. 18, No. 3. pp. 217-221.
@article{6c36f152304b4dfd85692d5315a83d26,
title = "Aspirin increases nitric oxide formation in chronic stable coronary disease",
abstract = "Introduction: There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation. Materials and Methods: In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.5, 325, 650, or 1300 aspirin for 12 weeks. Primary prespecified outcome measures were changes in heme oxygenase (HO-1), a downstream target of NO formation, and asymmetrical dimethyl arginine (ADMA), a competitive inhibitor of NO synthase. Results: There were no significant differences for HO-1 or ADMA between any of the clinically relevant doses of aspirin tested, so all were combined. For HO-1, there was a significant increase (10.29 ± 2.44, P <.001) from baseline (15.37 ± 1.85) to week 12 (25.66 ± 1.57). The mean ratio (MR) of week 12 to baseline for HO-1 was significantly higher than 1.0 (1.67, confidence interval [CI] from 1.60 to 1.74, P <.001). For ADMA, there was a significant decrease (-0.24 ± 0.11, P <.001) from baseline (0.78 ± 0.08) to week 12 (0.54 ± 0.07). The MR of week 12 to baseline for ADMA was significantly lower than 1.0 (0.69, CI from 0.66 to 0.73, P <.001). Conclusions: In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA. These are the first randomized data on secondary prevention patients. These data support the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary.",
keywords = "Aspirin, Atherosclerosis (4 limit = 5), Nitric oxide",
author = "Scott Hetzel and David DeMets and Ricky Schneider and Steven Borzak and Wendy Schneider and Victor Serebruany and Henning Schr{\"o}der and Hennekens, {Charles H.}",
year = "2013",
month = "5",
doi = "10.1177/1074248413482753",
language = "English (US)",
volume = "18",
pages = "217--221",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Aspirin increases nitric oxide formation in chronic stable coronary disease

AU - Hetzel, Scott

AU - DeMets, David

AU - Schneider, Ricky

AU - Borzak, Steven

AU - Schneider, Wendy

AU - Serebruany, Victor

AU - Schröder, Henning

AU - Hennekens, Charles H.

PY - 2013/5

Y1 - 2013/5

N2 - Introduction: There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation. Materials and Methods: In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.5, 325, 650, or 1300 aspirin for 12 weeks. Primary prespecified outcome measures were changes in heme oxygenase (HO-1), a downstream target of NO formation, and asymmetrical dimethyl arginine (ADMA), a competitive inhibitor of NO synthase. Results: There were no significant differences for HO-1 or ADMA between any of the clinically relevant doses of aspirin tested, so all were combined. For HO-1, there was a significant increase (10.29 ± 2.44, P <.001) from baseline (15.37 ± 1.85) to week 12 (25.66 ± 1.57). The mean ratio (MR) of week 12 to baseline for HO-1 was significantly higher than 1.0 (1.67, confidence interval [CI] from 1.60 to 1.74, P <.001). For ADMA, there was a significant decrease (-0.24 ± 0.11, P <.001) from baseline (0.78 ± 0.08) to week 12 (0.54 ± 0.07). The MR of week 12 to baseline for ADMA was significantly lower than 1.0 (0.69, CI from 0.66 to 0.73, P <.001). Conclusions: In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA. These are the first randomized data on secondary prevention patients. These data support the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary.

AB - Introduction: There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation. Materials and Methods: In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.5, 325, 650, or 1300 aspirin for 12 weeks. Primary prespecified outcome measures were changes in heme oxygenase (HO-1), a downstream target of NO formation, and asymmetrical dimethyl arginine (ADMA), a competitive inhibitor of NO synthase. Results: There were no significant differences for HO-1 or ADMA between any of the clinically relevant doses of aspirin tested, so all were combined. For HO-1, there was a significant increase (10.29 ± 2.44, P <.001) from baseline (15.37 ± 1.85) to week 12 (25.66 ± 1.57). The mean ratio (MR) of week 12 to baseline for HO-1 was significantly higher than 1.0 (1.67, confidence interval [CI] from 1.60 to 1.74, P <.001). For ADMA, there was a significant decrease (-0.24 ± 0.11, P <.001) from baseline (0.78 ± 0.08) to week 12 (0.54 ± 0.07). The MR of week 12 to baseline for ADMA was significantly lower than 1.0 (0.69, CI from 0.66 to 0.73, P <.001). Conclusions: In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA. These are the first randomized data on secondary prevention patients. These data support the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary.

KW - Aspirin

KW - Atherosclerosis (4 limit = 5)

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84879240606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879240606&partnerID=8YFLogxK

U2 - 10.1177/1074248413482753

DO - 10.1177/1074248413482753

M3 - Article

C2 - 23524841

AN - SCOPUS:84879240606

VL - 18

SP - 217

EP - 221

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 3

ER -